# OnCo record paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020" ;
  schema:name "KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer"@en ;
  schema:description "Pembrolizumab shrank tumours in about a third of patients with mismatch repair-deficient cancers of many different organs, with responses that often lasted years; the pancreatic cancer group responded less often than most. It is the trial behind the tissue-agnostic approval for MSI-high cancer."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.19.02105>, <https://pubmed.ncbi.nlm.nih.gov/31682550/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.19.02105> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Marabelle A, Le DT, Ascierto PA, et al." ;
  onco:cancers <https://onco.cc/cancers/msi-high-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/nct02628067/> ;
  onco:people <https://onco.cc/people/aurelien-marabelle/>, <https://onco.cc/people/dung-le/> ;
  onco:journals <https://onco.cc/journals/jco/> .